https://www.onclive.com/view/dr-gerds-on-unmet-needs-in-low-risk-myelofibrosis
"Along with more vigilant surveillance, Gerds advocates for the development of therapies that can alter the disease progression course for patients with low-risk myelofibrosis. Given the proportion of patients whose disease progressed during the MOST trial, these findings point to the need for additional therapies that can alter the underlying disease, rather than simply managing symptoms, Gerds concludes."
https://www.onclive.com/view/dr-gerds-on-unmet-needs-in-low-risk-...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.003(6.67%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.5¢ | 4.2¢ | $37.11K | 834.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 244513 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 220000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |